An anonymous director reports

MEDIPHARM ANNOUNCES VOTING RESULTS FROM THE 2025 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Medipharm Labs Corp. has released the results of matters voted on at its annual and special meeting of holders of common shares held today.

There were 146 shareholders represented virtually or by proxy at the meeting holding an aggregate of 210,726,733 common shares, representing 50.76 per cent of Medipharm's total issued and outstanding common shares as at the record date for the meeting. As the meeting was held virtually, all resolutions were passed by way of ballot.

Shareholders approved the resolution to fix the number of directors at seven, approved the resolution appointing MNP LLP as auditor, elected all seven management director nominees and approved the resolution relating to unallocated awards under the company's equity incentive plan. Complete voting results for each of the matters presented at the meeting are provided herein.

Board changes

The company welcomes new directors Emily Jameson and John Medland to the board. Michael Bumby did not stand for re-election as a director at the meeting. The board thanks Mr. Bumby for his invaluable contributions. He was instrumental in the transformative Vivo acquisition, which has helped set Medipharm up for its next phase of growth.

Complete voting results from the meeting

Setting the number of directors at seven

The special resolution to fix the number of directors of the company at seven was approved by shareholders. Voting results are set out in an attached table.

Election of directors

The company's nominees were elected as directors of Medipharm for the ensuing year, or until their successors are elected or appointed. Voting results for each director nominee are set out in an attached table.

Appointment of auditor

MNP was appointed as auditor of Medipharm until the next annual meeting of the holders of the shareholders at a remuneration to be fixed by the directors. Voting results are set out in an attached table.

Approval of unallocated awards under equity incentive plan

A resolution to approve, among other things, the unallocated awards available under the company's equity incentive plan was approved by shareholders. Voting results are set out in an attached table.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products utilizing a GMP-certified (good manufacturing practices) facility with ISO-standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for the delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing practices licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the United States Food and Drug Administration.

In 2023, Medipharm acquired Vivo Cannabis Inc., which expanded Medipharm's reach to medical patients in Canada via the Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GmbH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

The company carries out its operations in compliance with all applicable laws in the countries in which it operates.

We seek Safe Harbor.